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Abstract
Purpose of Review Cost-effective care pathways are integral
to delivering sustainable healthcare programmes. Due to the
overestimation of coronary artery disease using traditional risk
tables, non-invasive testing has been utilised to improve risk
stratification and initiate appropriate management to reduce
the dependence on invasive investigations. In line with recent
technological improvements, cardiac CT is a modality that
offers a detailed anatomical assessment of coronary artery
disease comparable to invasive coronary angiography.
Recent Findings The recent publication of the National
Institute for Health and Care Excellences (NICE) Clinical
Guideline 95 update assesses the performance and cost utility
of different non-invasive imaging strategies in patients pre-
senting with suspected anginal chest pain. The low cost and
high sensitivity of cardiac CTmakes it the non-invasive test of
choice in the evaluation of stable angina. This has now been
ratified in national guidelines with NICE recommending car-
diac CTas the first-line investigation for all patients presenting
with chest pain due to suspected coronary artery disease.
Additionally, randomised controlled trials have demonstrated
that cardiac CT improves diagnostic certainty when incorpo-
rated into chest pain pathways.
Summary NICE recommend cardiac CT as the first-line test
for the evaluation of stable coronary artery disease in chest
pain pathways.
Keywords Coronary computed tomography angiography .
Chest pain . Angina . Coronary artery disease
Abbreviations
CACS Coronary artery calcium score
CAD Coronary artery disease
CTCA Computed tomography coronary
angiography
CMR Cardiac magnetic resonance
DSE Dobutamine stress echocardiography
EKG Electrocardiogram
ExSE Exercise stress echocardiography
ICA invasive coronary angiography
MI Myocardial infarction
MPS–SPECT Myocardial perfusion scintigraphy–single
positron emission computed tomography
NHS National Health Service




Despite decades of investment in the delivery of effective treat-
ment, cardiovascular disease remains responsible for the vast
majority of deaths worldwide. Even prior to the recent fluctu-
ations in the global financial climate, many modern healthcare
This article is part of the Topical Collection on Cardiac Computed
Tomography




1 University of Edinburgh/British Heart Foundation Centre for
Cardiovascular Science, Chancellor’s Building, 49 Little France
Crescent, Edinburgh EH16 4SB, UK
2 Department of Cardiology, Royal Brompton Hospital and Harefield
NHS Trust, Sydney Street, London SW3 6NP, UK
Curr Cardiovasc Imaging Rep (2017) 10: 15
DOI 10.1007/s12410-017-9412-6
economies had sharpened their focus on delivering healthcare
that is both clinical and cost effective. Ensuring cost-effective
and efficacious treatment is central to maintaining sustainable
healthcare programmes as populations increase in age and ac-
cess healthcare in greater numbers. In the UK, the National
Institute for Health and Care Excellence (NICE) routinely re-
views clinical evidence and publishes advice and recommen-
dations based on the combination of clinical efficacy and cost
effectiveness of both therapies and technologies. Established in
1997, it is now enshrined in UK law to ensure patients cared for
in the English National Health Service (NHS) gain benefits
from cost-effective measures, and that NHS resources are
optimised.
Guidelines on the investigation and management of coronary
artery disease (CAD) have evolved significantly over the past
two decades. In the early 1990s, Braunwald’s Quick Reference
Guide for Clinicians recommended patients were offered treat-
ment based on their pre-test probability of angina, and a clear
history of anginal chest pain was a pre-requisite for stratifying
which patients required downstream investigation [1]. Non-
invasive testing (predominantly exercise-EKG) was reserved
for identifying high-risk patient groups that may benefit from
additional medical therapy and coronary revascularisation.
Since Braunwald’s early publication, the expansion of
multi-modality cardiac imaging has generated a number of
different testing strategies with improved sensitivity for diag-
nosing CAD that have been incorporated into national [2] and
international guidelines [3, 4]. Due to the risk of potential
complications following the onset of chest pain symptoms,
clinical practice now focuses on the rapid clinical assessment
of patients with suspected angina to select out high-risk indi-
viduals [5].
Prior to being updated in November 2016, the UK NICE
recommendations on the investigation of stable chest pain
involved eliciting a careful history of symptoms and estima-
tion of the pre-test likelihood (PTL) of significant CAD using
a modified Diamond-Forrester model [6] to select the appro-
priate non-invasive test for improving diagnostic certainty of
CAD [2]. Only those with typical and atypical angina symp-
toms with a >10% PTL of obstructive CADwere recommend-
ed for cardiac investigations to confirm the diagnosis angina
secondary to obstructive CAD. In patients with a PTL <10 or
>90%, no cardiac investigation was recommended. If patients
had a PTL >90%, invasive coronary angiography was re-
served for those who remained symptomatic despite optimal
medical therapy for stable angina or in asymptomatic cases
where there was a suspicion of prognostically significant
CAD that may benefit from coronary revascularisation. If
the PTL was low (10–29%), a Coronary Artery Calcium
Score (CACS) was the recommended first-line investigation
with subsequent CT coronary angiography (CTCA) if the cal-
cium score was between 1 and 400 Agatston Units. If the PTL
was intermediate (30–60%), non-invasive functional imaging
was recommended as the first-line investigation, with invasive
coronary angiography (ICA) recommended for those with a
high PTL (61–90%). Adherence to this guideline provided
considerable cost savings, namely from a reduction in the
number of expensive ICAs in spite of a more costly initial
non-invasive testing strategy [7].
Several concerns were subsequently raised about the 2010
NICE guidelines and many were fundamental to the recent
revision. First, the reduction in the prevalence of CAD sec-
ondary to the increased use of therapy for risk factor modifi-
cation led to the modified Diamond-Forrester model signifi-
cantly overestimating the frequency of significant CAD, par-
ticularly in women [8]. Clearly, the use of a PTLmodel is only
valid in risk stratification if it identifies and groups patients
accurately and reproducibly.
Second, there was concern about the minimal use of ana-
tomical assessment of CAD that was limited to CACS and
ICA in those with the lowest and highest PTL. Moreover,
the evidence base for CACS was based on data from asymp-
tomatic patients, not those with symptoms [9]. As such, the
appropriateness of CACS as the first-line investigation with
subsequent CTCA reserved for those with a CACS between 1
and 400 AU was challenged [10] with the UK Royal College
of Radiologists stating CTCAwould be reasonable to perform
in those with a CACS of 0.
Third, even in 2010, CTCA assessment was likely to
be beneficial in those with both low and intermediate PTL
[11] and functional imaging for all intermediate PTL
would undoubtedly lead to both false-positive and false-
negative results based on sensitivity and specificity of
these techniques [12, 13].
Thus, the updated 2016 NICE guideline is notable for its
removal of the pre-test probability model and the use of
CTCA as the first-line investigation in all patients with atyp-
ical or typical angina symptoms or those who are asymptom-
atic with suggested EKG changes for ischemia [14]. It has
been argued that service provision for those with stable
CAD should be tailored towards the needs of the population
to optimise cost-efficacy in a testing strategy that is most ap-
plicable to the low-intermediate PTL group of patients, as this
would cover the majority of patients presenting to chest pain
clinics [15]. Thus, a test with a high negative predictive value
has great merit in the assessment of patients with suspected
angina due to CAD.
Is this anatomical-guided strategy supported by the evi-
dence? Historically, ICA has been the definitive test to con-
firm of the presence of CAD against which all other non-
invasive tests have been validated. However, ICA is the most
expensive diagnostic investigation and, importantly, exposes
individuals to the highest risk of procedural complications
[14]. In the 2016 update, NICE determined the clinical effec-
tiveness of the non-invasive modalities against a “gold stan-
dard” of 50% stenosis on ICA, the same methodology that
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was used in the previous guidelines issued in 2010.
Confirming the presence of a coronary artery luminal stenosis
of 50% or greater is only part of the diagnostic assessment.
Confirmation of inducible myocardial ischemia has been the
principal goal prior to the initiation of appropriate of second-
ary prevention treatment and coronary revascularisation. In
the NICE guidelines, functional imaging is still recommended
for those who have significant CAD or equivocal findings on
CTCA. It should also be noted however that whilst non-
invasive testing can assess multiple levels of the ischemia
cascade, it is ultimately the confirmation of the anatomical
burden of CAD which determines an individual’s future risk
of cardiac events [16].
Clinical Effectiveness of CTCA against ICA
As part of the 2016 update, NICE evaluated the diagnostic
accuracy of the main non-invasive testing strategies against
the presence of obstructive coronary artery luminal stenosis
on ICA. Established stress testing modalities using dobutamine
or exercise stress echocardiography (DSE/ExSE), myocardial
perfusion scintigraphy (MPS)–single photon emission comput-
ed tomography (SPECT), and cardiac magnetic resonance im-
aging (CMR) have comparable levels of diagnostic accuracy,
which is reflected by the relatively few novel publications in
this field. Conversely, the evolution of computed tomography
(CT) has resulted in technological developments providing in-
creased volume coverage and shorter gantry rotation times that
significantly improve the diagnostic utility at much reduced
levels of radiation exposure. The enhanced spatial and temporal
resolution of modern cardiac CT scanners offer an extremely
high sensitivity (0.96, 95% CI 0.94–0.97) for detecting the
presence of coronary artery plaque when compared to ICA.
The majority of the studies included in the NICE meta-
analysis were composed of populations with a higher preva-
lence of coronary artery disease than is often found in the un-
selected population that are referred to cardiology clinics for
assessment. This may account for the wider variation seen in
the specificity of cardiac CT (0.79, 95% CI 0.72–0.84), albeit
no significant bias was observed following sensitivity analysis
(0.79, 95% CI 0.73–0.85, I2 79%). It is no surprise that when
compared with ICA, an anatomical assessment using cardiac
CToutperforms all other stress testing modalities. However, of
greater importance is the ability to avoid more costly and po-
tentially harmful invasive investigation (non-fatal complication
74 per 10,000 (ICA) versus 3.2 per 10,000 (CTCA) [14].
Cost Effectiveness of CTCA
NICE’s cost utility analysis of a diagnostic test aims to calculate
the incremental cost and benefit of care pathways using
different investigation strategies. The health economics of care
pathways have come under greater scrutiny due to increasing
financial pressures on healthcare providers. Only two studies
have been published that reflect both the UK costs of investi-
gation for CAD and measurable health benefit by either
quality-adjusted life year or correct diagnosis [17, 18].
Genders et al. investigated 16 different diagnostic strategies
involving cardiac CT, CMR, echocardiography and MPS-
SPECT. A lifetime time horizon and Markov state-transition
model were applied to a simulated population of 60-year-olds
with no history of coronary artery disease. By applying cost-
ings from 2011, DSE was the most cost-effective test. The
NICE cost utility analysis used tariffs derived from NHS refer-
ence costs (CTA £122.11, DSE £271.31, MPS-SPECT
£367.29, CMR £515, ICA £1684.71) and cardiac CT was, by
far, the lowest-cost test per correct diagnosis due to the low cost
of the test and high sensitivity and low probability of fatal or
non-fatal complication. Figure 1 demonstrates graphically the
cost and clinical effectiveness of various strategies in a simple
to understand format. Interestingly, economic modelling deter-
mined that only if the cost of cardiac CT tripled would it cease
to be the least cost-effective initial investigation, and even then
the next most cost-effective strategy was a combination of
CTCAwith DSE (cost at which CTCA is no longer cost-effec-
tive, 20% pre-test probability £394.95, 45% pre-test probability
£494.84, 75% pre-test probability £710.32).
NICE has calculated that the use of CTCA as a first-line
investigation will generate annual savings of £16 million in
England alone, by prompt exclusion of significant CAD and
more effectively use of NHS resources. [19]Modelling for US
tariffs has not been performed, but cost components based on
the cost utility analysis of the PROMISE study compare
favourably [20] and the UK modelling is likely to be broadly
applicable in other healthcare settings.
Beyond the NICE Guidelines
Whilst the UK NICE guidelines give a clear picture as to the
most clinically and cost-effective modality based on a 50%
stenosis on ICA as a gold standard, there are additional argu-
ments for the use of CTCA as a first-line investigation in this
population. The ideal diagnostic test for CAD should influ-
ence downstream decision-making to reduce cardiac death
and non-fatal myocardial infarction. To facilitate a reduction
in cardiac events, the first-line diagnostic test should have a
high level of diagnostic accuracy, the ability to better risk
stratify individuals into different treatment regimens and be
integrated into a cost-effective clinical pathway.
Until recently, most studies that have compared different
stress imaging modalities to detect obstructive CAD have
found no definitive evidence to recommend the superiority
of one diagnostic test over another [21, 22]. Diagnostic
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evaluation using functional testing has received significant
criticism due to the high rate of false-positive results.
Registry data have highlighted the low prevalence of ob-
structive CAD following elective ICA, despite prior stratifi-
cation with functional testing to identify prognostically sig-
nificant myocardial ischemia [23, 24]. The low diagnostic
yield of actionable CAD using functional testing has gener-
ated a debate as to which test is best placed to serve as a
‘gatekeeper’ to ICA. The recent publication of Clinical
Evaluation of Magnetic Resonance Imaging in Coronary
Artery Disease 2 (CE-MARC-2) supported the rationale for
non-invasive testing prior to ICA, owing to risk models
overestimating the presence of obstructive CAD as previous-
ly discussed [21]. With the multitude of non-invasive tests
available, ICA is only rarely required to confirm the diag-
nosis of obstructive CAD and should be reserved for those
likely to have coronary intervention. At the time of the
NICE guideline review, two ‘test-and-treat’ multicentre
randomised control trials were published that provided in-
sight into whether CTCA could be incorporated into chest
pain care pathways to improve diagnostic accuracy and risk
stratification of coronary artery disease [22, 25]. Both trials
were discussed in the update of the NICE recommendations,
as they have laid new ground for evaluating the efficacy of
non-invasive imaging tests, namely in determining whether
their incorporation into a care pathway actually confers ben-
efit to patients. They also offer an opportunity to assess the
merits of using an anatomical-guided strategy in chest pain
pathways in a combined cohort of over 14,000 patients
(Table 1).
The Prospective Multicenter Imaging Study for
Evaluation of chest pain (PROMISE) trial was a prag-
matic trial that recruited a large cohort from USA and
Canadian centres to determine whether an initial assess-
ment of suspected stable CAD using CTCA reduces ma-
jor adverse cardiovascular events [22]. There was no im-
provement in death, myocardial infarction or major pro-
cedural complication after a median of 2-years of follow-
up when compared with a functional-guided strategy.
The Scottish Computed Tomography of the HEART
(SCOT-HEART) trial recruited patients referred for re-
cent onset chest pain to cardiology clinics with suspected
angina [25]. The trial population reflected standard UK
practice, all of whom presented with chest pain and one
third reported typical angina symptoms. In the CTCA
arm, a higher rate of obstructive CAD was reported com-
pared with the PROMISE trial (Table 1), and, of note,
there was a borderline but non-significant reduction in
cardiac death and myocardial infarction (hazard ratio
0.62, 95% confidence interval 0.38–1.01, p = 0.0527).
Subsequent post hoc landmark analysis from the time
of clinical intervention (at 50 days), namely the point
when clinicians reviewed the test result and dispensed
preventive medical therapy, was associated with a halv-
ing of the rate of cardiac death and myocardial infarction
(hazard ratio 0.50, 95% confidence interval 0.28–0.88,
p = 0.020) [26]. This signal is consistent with observa-
tional data from the CONFIRM registry showing that
initiation of statin therapy in individuals with subclinical






























Fig. 1 NICE cost-effectiveness analysis of diagnostic tests in 45% pre-
test likelihood population. [14]. The figure plots the average proportion of
correct diagnoses (effectiveness) versus the average cost (£ sterling) of
each testing strategy. A first-line testing strategy using CT coronary
angiography has the lowest cost per correct diagnosis of coronary artery
disease. The cost-effectiveness frontier is represented by a line connecting
no testing, CTcoronary angiography, and invasive coronary angiography.
All other testing strategies lie beneath this line and have fewer correct
diagnoses at a higher cost
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Challenges to the Implementation of the Updated
NICE Guideline
The publication of the updated NICE guideline CG95 poses
some major challenges to the cardiovascular imaging commu-
nity. First, a significant increase in the availability of CTCA is
required for UK centres to comply with the updated NICE
recommendations. An estimate by the British Society of
Cardiovascular Imaging/British Society of Cardiovascular
CT (BSCI/BSCCT) is that a 700% increase in cardiac CTwill
be required across the UK [28]. In order to fulfil this service
commitment, substantial investment in CT technology and
training will be required. The UK has a relatively low number
of CT scanners per head of population compared to other
countries in Europe and the USA [29], and whilst centres that
already perform a high volume of cardiac CTwill have fewer
delivery challenges than the low volume centres, there are
currently no centres in the UK which are meeting the required
targets for compliant delivery of cardiac CT imaging.
Second, there will also be implications for functional im-
aging modalities which are more difficult to define. Concerns
involve the potential disinvestment in stress imaging services
in favour of CT imaging. Whilst a second-line stress test may
be required in a proportion of patients who undergo CTCA, it
is unknown how this will affect the service utilisation of func-
tional imaging. The increased use of CTCA will generate
greater numbers of positive and equivocal CTCA and there-
fore the requirement for functional imaging will likely not
decline significantly.
Third, in addition to increasing the volume of cardiac CT
that is performed, it is essential that quality is maintained in
order to maintain the high diagnostic accuracy of CTCA. This
includes optimisation of image quality, providing informative
reports of studies and minimising radiation dose exposure.
Guidelines for the optimal acquisition of cardiac CT have
been published by national and international groups, and these
should be followed in order to optimise image quality in car-
diac CT [30, 31]. Guidelines are also available for the struc-
tured reporting of cardiac CT which may help with the com-
munication of results to clinicians and patients [32]. This may
also assist in the rationalisation of downstream investigations
and prevent a reactionary increase in the use of invasive cor-
onary angiography when cardiac CT identifies non-
obstructive CAD.
Finally, the emergence of cardiac CT has correlated with a
debate on the revision of atherosclerotic coronary artery dis-
ease classification [33]. Categorising CAD on the basis of
stenosis severity alone fails to account for the continuum of
risk associated with non-obstructive atherosclerotic plaque.
Indeed, improved risk stratification of future cardiac events
may be achieved by identifying features of vulnerability in
metabolically active plaques rather than relying on luminal
Table 1 Anatomical-guided strategy using cardiac CT in a combined cohort of over 14,000 patients











Intervention CTCA in addition to standard care CTCA versus functional test
Control Standard care




Nuclear stress imaging (67.3%)
Stress echocardiography (22.5%)
Exercise EKG (10.2%)
Primary outcome Certainty of diagnosis of angina due to coronary heart
disease at 6 weeks
All cause mortality, non-fatal MI, hospitalisation for unstable
angina, major procedural complications
CTCA (n = 2073) Standard care (n = 2073) CTCA (n = 4996) Functional test (n = 5007)
CAD, >50% stenosis (n) 42% (752) – 10.3% (517) –
All-cause death/non-fatal MIa (n) 1.9% (39) 2.7% (55) 2.1% (104) 2.2% (112)
Cardiac death/non-fatal MIa b 1.3% (26) 2.0% (42) – –
Non-fatal MIa (n) 1.1% (22) 1.7% (35) 0.6% (30) 0.8% (40)
Revascularisation (n) 11.2% (233) 9.7% (201) 6.2% (311) 3.2% (158)
Cardiac death/non-fatal MI in
revascularisation group (n)
8% (18) 14% (28) – –
a SCOT-HEART median follow-up 1.7 years, PROMISE median follow-up 2 years
b SCOT-HEART hazard ratio 0.62, 95% confidence interval 0.38–1.01, p = 0.0527
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narrowing in isolation [34]. Whilst currently there is no clear
guidance on how to manage non-obstructive CAD, there is
growing recognition that this is currently an unmet public
health problem, particularly in women [35].
Conclusion
The update to the UK NICE guidelines recommends that car-
diac CT is the first-line investigation for patients presenting
with new-onset chest pain due to suspected CAD. This guide-
line is based primarily on the diagnostic accuracy and cost
effectiveness of this strategy, using ICA stenosis as the gold-
standard. In addition, the inability of cardiovascular risk as-
sessment to adequately differentiate between groups of pa-
tients means that this has been removed from the updated
NICE recommendations. An anatomical investigation strate-
gy, such as proposed in the 2016 NICE guidelines, is support-
ed by recent large-scale randomised controlled trials using
cardiac CT in both the UK and USA. The implementation of
these guidelines requires a large increase in the number of CT
scans that are performed; however, the projected cost savings
of $20 million per annum, in England alone, mean that the
short-term investment is likely to be justified.
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